Although the results of both prospective and retrospective design subgroup analysis shown that high pre-treatment serum AFP-L3% implied poor OS and DFS without significant heterogeneity in the data (p-value for overall effect <0.05), validation of the prognostic value of AFP-L3% in HCC in more prospective studies is required. This evidence concerns the gene AFP and hepatocellular carcinoma.